Announcing the International Prognostic Score for NLPHL (LP-IPS) in @JCO_ASCO, the largest study of NLPHL to date. Congratulations to our founders Drs. @michaelsbinkley & @JamieFlerlage and the GLOW team on this high-impact publication. #NLPHLsm #lymsm

We were also happy to present Dr. Yasodha Natkunam with the Suzi Birz Commitment to Collaboration Award this year for her ongoing work with GLOW and for making our WHO and ICC panel at this summit come to fruition. #lymsm #NLPHLsm cc @suzibirz

Thank you to all who attended our third @glow_nlphl Summit yesterday to discuss NLPHL classification. We thank Drs. Elias Campo, Daphne de Jong, Sylvia Hartmann, Richard Hoppe, & Leticia Quintanilla-Fend, and our AYA patient advocate William Martins, for sharing their expertise.

Thrilled our study exploring cell state ecosystems for NLPHL has been published. This represents a multi-year effort and the best collaborators in the world. Thread to follow. https://t.co/tp5jLUKC8l @glow_nlphl @JamieFlerlage @AshAlizadeh @everettmoding @vit_prochazka

Our @glow_nlphl lead Dr. @JamieFlerlage spoke about the GLOW multicenter study of radiation therapy outcomes for Stage IA NLPHL which she presented at #18ICML for @VJHemOnc. #lymsm #NLPHLsm https://t.co/XKjBaPeXgs

Congratulations to Dr. Juliana Costa on presenting @glow_nlphl at Congreso @ACHOP_COL in Colombia and how to establish NLPHL registries in Latin America. Additional thanks to Drs. Ana Rosa Braz Costa and Adriana Morais for their leadership on this work. #lymsm #NLPHLsm

Proud to work with this incredible group of investigators and patients @glow_nlphl on studying patient-reported outcomes and the patient experience in this rare disease. #18ICML #lymsm

Outcomes Stage IA NLPHL @glow_nlphl: superior PFS (not OS) for RT after complete resection (vs observation). For unresected patients, best PFS with RT & RT+ABVD, no diff OS. No diff in transformation events. More numerical SPMs after RT. #lymsm #18ICML

Resection + RT improves PFS vs observation alone (90% vs 65%) for NLPHL presented by @JamieFlerlage #ICML18 @glow_nlphl

Congratulations to Dr. @JamieFlerlage on her oral presentation at #18ICML on our @glow_nlphl analysis of radiotherapy in Stage IA NLPHL. #lymsm

You can observe advanced-stage NLPHL just like other indolent lymphomas. No compromised PFS2 for patients who are initially observed. And only 1/3 of patients needed treatment. #18ICML #lymsm @glow_nlphl

Transformation not uncommon in NLPHL, more common with Pattern E (I always ask hematopathology to identify pattern) and splenic involvement. #18ICML #lymsm #NLPHLsm

NLPHL session at #18ICML. Fascinating work about association of NLPHL with bacterial infections in patients with certain HLA types. #lymsm #NLPHLsm cc @glow_nlphl

Congratulations to all our @glow_nlphl contributing centers on establishing the first prognostic index specifically for NLPHL. #lymsm #18ICML

We are seeking patients with relapsed or refractory FL or DLBCL for a compensated study about experiences with bispecific antibody therapies. To my #lymsm & #onctwitter colleagues: please share the attached flyer with your networks. Thank you! #tcellrx

To my lymphoma colleagues: we are performing a study of patient experiences with bispecific antibodies for relapsed/refractory DLBCL or FL. Please share this flyer with your patient groups and networks. Thank you! #lymsm

Read the editorial written about our @glow_nlphl research roadmap manuscript in Pediatric Blood & Cancer: https://t.co/Qj3dtbCWuH #lymsm #nlphlsm

Our @glow_nlphl research roadmap for NLPHL is now published. In this manuscript, we review the historical research challenges in NLPHL research and progress to date of our international GLOW Consortium ( https://t.co/AEHGTnZZaF). #lymsm #nlphlsm https://t.co/A4McCUfZZP

"A diagnosis of NLPHL is often a long, confusing, and isolating journey." Our @glow_nlphl study of patient & care partner perspectives on NLPHL, and how we can better counsel on management options. Many thanks to our collaborating patient advocates. #lymsm https://t.co/vPNX1L6JPu

Announcing our latest @glow_nlphl study, a qualitative analysis of patient & care partner perspectives on treatment decision-making in NLPHL. This study enables investigators to better align NLPHL research with patient priorities. #lymsm #nlphlsm https://t.co/iuNf9noxE6

The LP-IPS prognostic score for NLPHL, developed through the @glow_nlphl consortium, was just cited in a new review published by Drs. Eichenauer & Borchmann. #lymsm #NLPHLsm https://t.co/MtsnX0pCdg